SARS-CoV-2 seroconversion in children attending daycare versus adults in Germany between October 2020 and June 2021.
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
15 Sep 2023
15 Sep 2023
Historique:
received:
07
12
2022
accepted:
31
08
2023
medline:
16
9
2023
pubmed:
16
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
Data on seroconversion rates after SARS-CoV-2 infection in young children (<6 years) is scarce. The present study compares seroconversion rates between young children and adults and identifies associated factors. The COALA study ("Corona-outbreak-related examinations in daycare centers") investigated transmission dynamics of SARS-CoV-2 in daycare centers and associated households (10/2020-06/2021). 114 individuals tested positive for SARS-CoV-2 through PCR either prior to the study period by health authorities or in PCR testing during the study period. Two capillary blood samples were obtained within five weeks consecutively and tested for SARS-CoV-2 IgG-antibodies (second sampling depending on positive PCR). Results from 91 participants (38 young children 1-6 years, 53 adults) were included in the analyses. Seroconversion rate in young children is significantly higher than in adults (97.4% versus 66%). High viral load and longer time interval between the probable date of infection and antibody testing are associated with seroconversion. Our findings depict substantial development of specific antibodies in young children after SARS-CoV-2 infection. This may provide temporary protection from re-infection for young children or severe disease for this age group. When fighting an infectious disease, the immune system often produces antibodies. These proteins circulate in the blood, where they help to clear the infection and generally remain present for several months after recovery. Little is known about how often children younger than 6 years develop antibodies after SARS-CoV-2 infection. The aim of our study was to compare antibody development of young children and adults. We examined blood samples from young children and adults after SARS-CoV-2 outbreaks in daycare centers during the early pandemic (10/2020–06/2021) in Germany. Young children and adults who tested positive for SARS-CoV-2 had two blood samples taken at an interval of five weeks. We found that young children are more likely to develop antibodies after SARS-CoV-2 infection than adults. These findings indicate that young children may be—at least temporarily—protected from re-infection or from a severe course of the disease.
Sections du résumé
BACKGROUND
BACKGROUND
Data on seroconversion rates after SARS-CoV-2 infection in young children (<6 years) is scarce. The present study compares seroconversion rates between young children and adults and identifies associated factors.
METHODS
METHODS
The COALA study ("Corona-outbreak-related examinations in daycare centers") investigated transmission dynamics of SARS-CoV-2 in daycare centers and associated households (10/2020-06/2021). 114 individuals tested positive for SARS-CoV-2 through PCR either prior to the study period by health authorities or in PCR testing during the study period. Two capillary blood samples were obtained within five weeks consecutively and tested for SARS-CoV-2 IgG-antibodies (second sampling depending on positive PCR). Results from 91 participants (38 young children 1-6 years, 53 adults) were included in the analyses.
RESULTS
RESULTS
Seroconversion rate in young children is significantly higher than in adults (97.4% versus 66%). High viral load and longer time interval between the probable date of infection and antibody testing are associated with seroconversion.
CONCLUSIONS
CONCLUSIONS
Our findings depict substantial development of specific antibodies in young children after SARS-CoV-2 infection. This may provide temporary protection from re-infection for young children or severe disease for this age group.
When fighting an infectious disease, the immune system often produces antibodies. These proteins circulate in the blood, where they help to clear the infection and generally remain present for several months after recovery. Little is known about how often children younger than 6 years develop antibodies after SARS-CoV-2 infection. The aim of our study was to compare antibody development of young children and adults. We examined blood samples from young children and adults after SARS-CoV-2 outbreaks in daycare centers during the early pandemic (10/2020–06/2021) in Germany. Young children and adults who tested positive for SARS-CoV-2 had two blood samples taken at an interval of five weeks. We found that young children are more likely to develop antibodies after SARS-CoV-2 infection than adults. These findings indicate that young children may be—at least temporarily—protected from re-infection or from a severe course of the disease.
Autres résumés
Type: plain-language-summary
(eng)
When fighting an infectious disease, the immune system often produces antibodies. These proteins circulate in the blood, where they help to clear the infection and generally remain present for several months after recovery. Little is known about how often children younger than 6 years develop antibodies after SARS-CoV-2 infection. The aim of our study was to compare antibody development of young children and adults. We examined blood samples from young children and adults after SARS-CoV-2 outbreaks in daycare centers during the early pandemic (10/2020–06/2021) in Germany. Young children and adults who tested positive for SARS-CoV-2 had two blood samples taken at an interval of five weeks. We found that young children are more likely to develop antibodies after SARS-CoV-2 infection than adults. These findings indicate that young children may be—at least temporarily—protected from re-infection or from a severe course of the disease.
Identifiants
pubmed: 37714948
doi: 10.1038/s43856-023-00352-3
pii: 10.1038/s43856-023-00352-3
pmc: PMC10504330
doi:
Types de publication
Journal Article
Langues
eng
Pagination
124Subventions
Organisme : Bundesministerium für Gesundheit (Federal Ministry of Health, Germany)
ID : ZMVI1-2520COR404
Informations de copyright
© 2023. Springer Nature Limited.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Infez Med. 2021 Jun 1;29(2):216-223
pubmed: 34061786
Nat Commun. 2022 Jan 10;13(1):128
pubmed: 35013206
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Microbiol Spectr. 2021 Oct 31;9(2):e0008721
pubmed: 34468184
JAMA Netw Open. 2022 Mar 1;5(3):e221313
pubmed: 35262717
Microbiol Res. 2022 Nov;264:127145
pubmed: 35973364
Arch Dis Child. 2020 Dec 1;:
pubmed: 33262177
Swiss Med Wkly. 2021 Sep 17;151:w30058
pubmed: 34546012
Virol J. 2021 Jun 2;18(1):110
pubmed: 34078394
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Pediatr Infect Dis J. 2022 Feb 1;41(2):e36-e45
pubmed: 34966142
Elife. 2021 Jul 12;10:
pubmed: 34250907
Children (Basel). 2022 Feb 12;9(2):
pubmed: 35204966
Epidemiol Infect. 2022 Jul 08;150:e141
pubmed: 35912971
Front Public Health. 2021 Dec 13;9:773850
pubmed: 34976930
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Nat Commun. 2022 Nov 23;13(1):7185
pubmed: 36434068
Children (Basel). 2022 May 05;9(5):
pubmed: 35626842
Pediatr Infect Dis J. 2021 Aug 1;40(8):e294-e299
pubmed: 34250968
Monatsschr Kinderheilkd. 2022;170(12):1113-1121
pubmed: 36405627
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
Front Pediatr. 2022 Nov 14;10:989456
pubmed: 36452353
PLoS One. 2022 Aug 17;17(8):e0272663
pubmed: 35976947
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920